Gut, microbiota-dependent trimethylamine- N -oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease

Ottiger, Manuel; Nickler, Manuela; Bernasconi, Luca; Huber, Andreas; Henzen, Christoph; Hoess, Claus; Thomann, Robert V.; Zimmerli, Werner; Müeller, Beat; Schuetz, Philipp

doi:10.1016/j.nut.2017.07.001

Cited by 51 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alterations of the gut microbiome influence the incidence and progression of not only gastric carcinogenesis (17), but also extra-intestinal cancers, such as breast and hepatocellular carcinoma, presumably through inflammatory and metabolic circuitries (18). Meanwhile, gut microbiota was also found contribute to the acute lung injury (19), the exacerbation of chronic obstructive pulmonary disease (COPD) (20), and the development of asthma (21), which highlighted its important role in affecting the respiratory system. Actually the hypothesis of “gut–lung” axis has been raised 20 years ago, when study found that gut-derived injurious factors can reach to the lung and systemic circulation via the intestinal lymphatics (22).…”

Section: Discussionmentioning

confidence: 99%

Alteration of Gut Microbiome in Lung Cancer Patients

Fang

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death. Better 24 understanding of factors and pathways involved in lung cancer is needed to improve 25 diagnose and treatment strategies. Recent studies have provided insights into the 26 possible correlation between intestinal dysbiosis and cancer development. Although 27 the immunological relationship between gut and lung had been suggested by many 28 researches, however, to date, no study had investigated the characterization of gut 29 microbiome in treatment naïve lung cancer patients, whether it is distinct from that of 30 health individuals and contribute to the onset and development of lung cancer remain 31 unclear. In this study, we investigated whether gut microbiome of lung cancer patients 32 (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by 33 high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. 34 We also identified microbiota signatures specific for different histological types of 35 lung cancer, including SSC, ADC, and SCLC. The gut microbiome of lung cancer 36 patients is characterized by decreased relative abundance of Prevotella, and increased 37 bacteria groups such as Actinomyces, and Streptococcus, etc. We also detected a mild 38 structural shift in gut microbiome between ADC and SCLC patients. Our results 39 showed that the gut microbiome of lung cancer patients altered significantly 40 compared with healthy individuals. However, the association between microbial 41 dysbiosis and lung cancer is not clearly understood, future studies involving larger 42 cohorts and metagenomics, or metabolomics, may elucidate the correlations between 43 gut microbiota and lung cancer development. 44 IMPORTANCE This is the first report to show the alteration of gut microbiome in 45 4 lung cancer patients. Our results showed that the gut microbiome of lung cancer 46 patients altered significantly compared with healthy individuals. 47 48

show abstract

Section: Discussionmentioning

confidence: 99%

Alteration of Gut Microbiome in Lung Cancer Patients

Fang

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Besides the lung flora, the gut microbiota is involved in exacerbations, as suggested by the increased gastrointestinal permeability in patients admitted for COPD exacerbations (Sprooten et al, 2018). Whatever the permeability's origin (hypoxemia or proinflammatory status), the level of circulating gut microbiotadependent trimethylamine-N-oxide has been associated with mortality in COPD patients (Ottiger et al, 2018). This association being explained by comorbidities and age, its impact per se is not guaranteed.…”

Section: Chronic Respiratory Diseasesmentioning

confidence: 99%

The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks

Enaud

Prével

Ciarlo

et al. 2020

Front. Cell. Infect. Microbiol.

492

411

View full text Add to dashboard Cite

The gut and lungs are anatomically distinct, but potential anatomic communications and complex pathways involving their respective microbiota have reinforced the existence of a gut-lung axis (GLA). Compared to the better-studied gut microbiota, the lung microbiota, only considered in recent years, represents a more discreet part of the whole microbiota associated to human hosts. While the vast majority of studies focused on the bacterial component of the microbiota in healthy and pathological conditions, recent works have highlighted the contribution of fungal and viral kingdoms at both digestive and respiratory levels. Moreover, growing evidence indicates the key role of inter-kingdom crosstalks in maintaining host homeostasis and in disease evolution. In fact, the recently emerged GLA concept involves host-microbe as well as microbe-microbe interactions, based both on localized and long-reaching effects. GLA can shape immune responses and interfere with the course of respiratory diseases. In this review, we aim to analyze how the lung and gut microbiota influence each other and may impact on respiratory diseases. Due to the limited knowledge on the human virobiota, we focused on gut and lung bacteriobiota and mycobiota, with a specific attention on inter-kingdom microbial crosstalks which are able to shape local or long-reached host responses within the GLA.

show abstract

“…The gut microbiome-dependent and dietary-associated metabolite trimethylamine-N-oxide (TMAO) has been shown to be a risk-predicting biomarker for atherosclerosis and incident cardiovascular events [12][13][14][15]. In addition, an independent association of TMAO with long-term all-cause mortality has been found in patients with congestive heart failure (CHF), chronic kidney disease (CKD), community-acquired pneumonia, and COPD [16][17][18][19].COPD patients are at higher risk for cardiovascular diseases [20], which are the most likely cause of death in patients with mild to…”

Section: Introductionmentioning

confidence: 99%

Comprehensive profiling of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity

Chiu

Lee

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that reduces lung and respiratory function, with a high mortality rate. Severe and acute deterioration of COPD can easily lead to respiratory failure, resulting in personal, social, and medical burden. Recent studies have shown a high correlation between the gut microbiota and lung inflammation. In this study, we investigated the relationship between gut microbiota and COPD severity. Results A total of 60 COPD patients with varying severity according to GOLD guidelines were enrolled in this study. DNA was extracted from patients’ stool and 16S rRNA data analysis conducted using high-throughput sequencing followed by bioinformatics analysis. The richness of the gut microbiota was not associated with COPD severity. The gut microbiome is more similar in stage 1 and 2 COPD than stage 3+4 COPD. Fusobacterium and Aerococcus were more abundant in stage 3+4 COPD. Ruminococcaceae NK4A214 group and Lachnoclostridium were less abundant in stage 2-4, and Tyzzerella 4 and Dialister were less abundant in stage 1. However, the abundance of a Bacteroides strain was associated with eosinophil count and lung function. Conclusions This study suggests that no distinctive gut microbiota pattern is associated with the severity of COPD. The gut microbiome could affect COPD by gut inflammation shaping the host immune system.

show abstract

Gut, microbiota-dependent trimethylamine- N -oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease

Cited by 51 publications

References 36 publications

Alteration of Gut Microbiome in Lung Cancer Patients

Alteration of Gut Microbiome in Lung Cancer Patients

The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks

Comprehensive profiling of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity

Contact Info

Product

Resources

About